"
Team:Michigan
From 2014.igem.org
(Difference between revisions)
| (9 intermediate revisions not shown) | |||
| Line 45: | Line 45: | ||
<ul class = "sub-menu"> | <ul class = "sub-menu"> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Project/">Background</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Design/">Design</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Modeling/">Modeling</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Results/">Results</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Future/">Future Plans</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Accomplishments/">Accomplishments</a> |
</li> | </li> | ||
| Line 73: | Line 73: | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Human/">Human Practice</a> |
<ul class = "sub-menu"> | <ul class = "sub-menu"> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Outreach/">Outreach</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Economic/">Economic Analysis</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Covance/">Covance Partnership</a> |
</li> | </li> | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Collaborations/">Collaborations</a> |
</li> | </li> | ||
| Line 97: | Line 97: | ||
<li class = "nav-menu-item"> | <li class = "nav-menu-item"> | ||
| - | <a href = " | + | <a href = "https://2014.igem.org/Team:Michigan/Notebook/">Notebook</a> |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
</li> | </li> | ||
| Line 127: | Line 118: | ||
</div><!--- #header-container --> | </div><!--- #header-container --> | ||
</header><!--- #header --> | </header><!--- #header --> | ||
| - | <div style="background-color:#f1ed6f;height:120px;position:absolute;left:-5px;top:51px"></div> | + | <!--- <div style="background-color:#f1ed6f;width:994px;height:120px;position:absolute;left:-5px;top:51px"></div> --> |
| Line 134: | Line 125: | ||
<header id = "page-header" class = "center">, | <header id = "page-header" class = "center">, | ||
| - | <h1><font size="10 | + | <h1><font size="10"> MSBT</font></h1></p><font size="3"><font color="#191970"> University of Michigan iGEM Team </font></font color></p> |
</header><!--- #page-header --> | </header><!--- #page-header --> | ||
| - | <div style="height:400px;width:450px;position:relative;top:-7px"> <img src="https://static.igem.org/mediawiki/2014/4/46/2website_front.png" style="width:450px;height:400px"> </div> | + | <div style="height:400px;width:450px;position:relative;top:-7px"> <img src="https://static.igem.org/mediawiki/2014/4/46/2website_front.png" style="width:450px;height:400px;position:relative;left:213px"> </div> |
| + | <div style="width:1000px"></div> | ||
</div> | </div> | ||
| - | + | <p style="position:relative;width:903px;top:-14px;left:39px"> <font color="#888888"> Antibodies allow us to bind targets in a highly selective manner, giving them a paramount role in biotechnology and medicine. Antibody production remains difficult in <I>E. coli</I> because antibodies require an oxidizing environment to properly fold. We have constructed an expression system capable of secreting functional scFv (single chain fragment variable) antibodies by tagging them to OsmY, a naturally secreted protein. Fusions with OsmY are carried through the periplasm into the media; allowing disulfide bonds to form during translocation. We've demonstrated the utility of this system in the context of sensing <i>Salmonella</i>, the pathogen responsible for 23,000 hospitalizations in the US each year. To demonstrate efficacy of our purified scFv antibodies to bind antigen, we compared them to scFv antibodies purified from an industrial system using ELISA. Our construct has the potential of becoming a cost-effective industry applicable method for purifying scFv antibodies, as well as other proteins, in large quantities. </font> | |
| + | </p> | ||
| + | <p style="position:absolute;top:566px;left:38px"><font size="6"> <u>Abstract</u></font></p> | ||
</div><!--- #page-content --> | </div><!--- #page-content --> | ||
Latest revision as of 03:27, 18 October 2014
<! --
This is an announcement, click the Close button on the right and it will not show again until you restart your browser.
MSBT
University of Michigan iGEM Team
Antibodies allow us to bind targets in a highly selective manner, giving them a paramount role in biotechnology and medicine. Antibody production remains difficult in E. coli because antibodies require an oxidizing environment to properly fold. We have constructed an expression system capable of secreting functional scFv (single chain fragment variable) antibodies by tagging them to OsmY, a naturally secreted protein. Fusions with OsmY are carried through the periplasm into the media; allowing disulfide bonds to form during translocation. We've demonstrated the utility of this system in the context of sensing Salmonella, the pathogen responsible for 23,000 hospitalizations in the US each year. To demonstrate efficacy of our purified scFv antibodies to bind antigen, we compared them to scFv antibodies purified from an industrial system using ELISA. Our construct has the potential of becoming a cost-effective industry applicable method for purifying scFv antibodies, as well as other proteins, in large quantities.
Abstract
